ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

PTO/SB/08A (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/507,140
Filing Date	19 September 2005
First Named Inventor	NERI, Dario
Art Unit	1623
Examiner Name	
Attorney Docket Number	PUS-E005-105B

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 5,573,905	11/12/1996	LERNER et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	10/507,140
Filing Date	19 September 2005
First Named Inventor	NERI, Dario
Art Unit	1623
Examiner Name	
Attorney Docket Number	PUS-E005-105B

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1	MORGAN et al., Researches on Residual Affinity and Coordination. Part II. Acetylacetones of Selenium and Tellurium, J. Chem. Soc., 1920, p. 1456-65, Vol. 117	
	2	STROBEL et al., Single-site enzymatic cleavage of yeast genomic DNA mediated by triple helix formation, Nature, 1991, p. 172-74, Vol. 350	
	3	CULL et al., Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor, Proc Natl Acad Sci USA, 1992, p. 1865-69, Vol. 89	
	4	BRENNER et al., Encoded combinatorial chemistry, Proc Natl Acad Sci USA, 1992, p. 5381-83, Vol. 89	
	5	DISTEFANO et al., Energetics of cooperative binding of oligonucleotides with discrete dimerization domains to DNA by triple helix formation,	
		Proc Natl Acad Sci USA, 1993, p. 1179-83, Vol. 90	
	6	WINTER et al., Making antibodies by phage display technology, Annu. Rev. Immunol., 1994, p. 433-55, Vol. 12	
	7	NERI et al., High-affinity Antigen Binding by Chelating Recombinant Antibodies (CRAbs), J. Mol. Biol., 1995, p. 367-73, Vol. 246	
	8	SHUKER et al., Discovering High-Affinity Ligands for Proteins: SAR by NMR, Science, 1996, p. 1531-34, Vol. 274	
	9	BODER et al., Yeast surface display for screening combinatorial polypeptide libraries, Nat. Biotechnol., 1997, p. 533-37, Vol. 15	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	10/507,140
Filing Date	19 September 2005
First Named Inventor	NERI, Dario
Art Unit	1623
Examiner Name	
Attorney Docket Number	PUS-E005-105B

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	10	PINI et al., Design and Use of a Phage Display Library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel, J. Biol. Chem., 1998, p. 21769-76, Vol. 273	
	11	SCHAFFITZEL et al., Ribosome display: an in vitro method for selection and evolution of antibodies from libraries, J. Immunol. Methods, 1999, p. 119-35, Vol. 231	
	12	BOEHM et al., Structure-based library design: molecular modelling merges with combinatorial chemistry, Current Opinion in Chemical Biology, 2000, p. 283-86, Vol. 4	
	13	DREWS et al., Drug Discovery: A Historical Perspective, Science, 2000, p. 1960-64, Vol. 287	
	14	BRODY et al. Aptamers as therapeutic and diagnostic agents, J. Biotechnol., 2000, p. 5-13, Vol. 74	
	15	VITI et al., Design and Use of Phage Display Libraries for the Selection of Antibodies and Enzymes, Methods Enzymol., 2000, p. 480-505, Vol. 326	
	16	DESIDERIO et al., A Semi-synthetic Repertoire of Intrinsically Stable Antibody Fragments Derived from a Single-framework Scaffold, J. Mol. Biol., 2001, p. 603-15, Vol. 310	
	17	CHEN et al., Isolation of high-affinity ligand-binding proteins by periplasmic expression with cytometric screening (PECS), Nat. Biotechnol., 2001, p. 537-42, Vol. 19	
	18	GIOVANNONI et al., Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening, Nucleic Acids Res., 2001, p. 1-6, Vol. 29	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.L./

PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/507,140
Filing Date	19 September 2005
First Named Inventor	NERI, Dario
Art Unit	1623
Examiner Name	
Attorney Docket Number	PUS-E005-105B

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	19	~~VARIOUS AUTHORS, Issue of Biopolymers, 2001, p. 121-227, Vol. 56~~	
	20	OTTO et al. Dynamic combinatorial chemistry. Drug Discov. Today, 2002, p. 117-25, Vol. 7	

Examiner Signature	/Sue Liu/	Date Considered	02/20/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.